Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

(CSE:BNXT)

0.8300 UNCHANGED
Streaming Delayed Price Updated: 3:47 PM EDT, Oct 29, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about BNXT

< Previous 1 2 Next >
BioNxt Reports "Readiness to Grant" Patent Notification from the Eurasian Patent Organization
Via ACCESS Newswire
BioNxt Enters the Final Stretch Before Human Trials for Next-Generation MS Drug
BioNxt Solutions Inc. (CSE:BNXT) (OTCQB:BNXTF) (FSE:BXT), a bioscience company developing next-generation drug delivery technologies, has launched a 15-day dosing optimization study for its lead... 
Via PressReach
Topics Intellectual Property
BioNxt Launches 15-day Sublingual Cladribine Dosing Optimization Study in Preparation for Human Bioequivalence Study
VANCOUVER, BC / October 21, 2025 / BioNxt Solutions Inc. (“BioNxt” or the “Company”) (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in next-generation drug delivery technologies,... 
Via PressReach
Topics Intellectual Property
BioNxt Launches 15-day Sublingual Cladribine Dosing Optimization Study in Preparation for Human Bioequivalence Study
Via ACCESS Newswire
BioNxt Completes "Fast-Track" US Track One Patent Filing for Sublingual Delivery of Cladribine for the Treatment of Multiple Sclerosis
Via ACCESS Newswire
BioNxt Reports Update on Targeted Chemotherapy Drug Delivery Platform
Via ACCESS Newswire
BioNxt Reports Sublingual Cladribine Multiple Sclerosis Drug Milestones Including Large-Animal Study for Validation and Dosing Optimization
Via ACCESS Newswire
Terry Lynch Continues as Capital Markets Advisor and BioNxt Retains Investor Relations Professionals
Via ACCESS Newswire
BioNxt Advances Semaglutide Oral Dissolvable Film (ODF) Program with Successful Proof-of-Concept and Prototype Development
Via ACCESS Newswire
BioNxt Solutions Completes Up-Listing to The OTCQB Market
Via ACCESS Newswire
Semaglutide API Delivery Enables Start of Lab-Scale ODF Development at BioNxt
Via ACCESS Newswire
BioNxt Fast-Tracks U.S. Patent for MS Drug and Secures Broad Platform IP Covering Autoimmune Neurology Pipeline
Via ACCESS Newswire
BioNxt Solutions Reports Pending Patent Grants in Europe and Eurasia, Strengthening IP Protection for Proprietary Sublingual Cladribine-Based MS Treatment
Via ACCESS Newswire
BioNxt Delivers Positive Results in Patented Cladribine Sublingual Thin-Film Program and Completes Successful Formulation
Via ACCESS Newswire
BioNxt Solutions Introduces Targeted Chemotherapy Drug Delivery Platform for Precision Oncology
Via ACCESS Newswire
BioNxt's Sublingual Cladribine Program for MS Ready for Next Phase
Via ACCESS Newswire
BioNxt Launches Feasibility Study for Semaglutide Oral Thin Film as Alternative to Injection/Tablets
Via ACCESS Newswire
BioNxt Solutions Provides Bi-weekly MCTO Status Report
Via ACCESS Newswire
BioNxt Solutions Reports Formal Notice from the European Patent Office of Intention to Grant Patent
Via ACCESS Newswire
BioNxt Reports Expanded Research, Development and Commercialization Capability with Centralized Munich Laboratory
Via ACCESS Newswire
BioNxt Solutions Reports Expanded Patent Protection from the Eurasian Patent Organization
Via ACCESS Newswire
BioNxt Solutions Prepares for Human Bioequivalence Study For MS
Via ACCESS Newswire
Clarification of Promotional Activities
Via ACCESS Newswire
BioNxt Solutions Unveils Accelerated 90-Day Plan: Global Patent Advancements, MS Clinical Trial, and Anti-Aging Expansion
Via ACCESS Newswire
BioNxt Accelerates R&D with Move to Gen-Plus Laboratory in Munich, Germany, Expanding Drug Delivery Research Capabilities
Via ACCESS Newswire
BioNxt Solutions Expands Patent Protection for Drug Delivery Innovations Backed by Positive IPRP
Via ACCESSWIRE
BioNxt Solutions Reports Progress on BNT23001 Development for Multiple Sclerosis Treatment
Via ACCESSWIRE
BioNxt Solutions Announces Development of Sublingual Thin-Film for Semaglutide
Via ACCESSWIRE
BioNxt Announces Enhanced Sublingual Product Development Pipeline with Innovative Solutions for Autoimmune Diseases and Longevity
Via ACCESSWIRE
Terry Lynch Joins BioNxt as Capital Markets Advisor
Via ACCESSWIRE
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.